Critical Review: Lakefront Biotherapeutics American Depositary Shares (LKFT) vs. The Competition

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT – Get Free Report) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it weigh in compared to its competitors? We will compare Lakefront Biotherapeutics American Depositary Shares to similar companies based on the strength of its institutional ownership, analyst recommendations, valuation, dividends, risk, profitability and earnings.

Insider & Institutional Ownership

32.5% of Lakefront Biotherapeutics American Depositary Shares shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are owned by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Lakefront Biotherapeutics American Depositary Shares and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lakefront Biotherapeutics American Depositary Shares 0 5 3 0 2.38
Lakefront Biotherapeutics American Depositary Shares Competitors 9874 15295 45659 1600 2.54

Lakefront Biotherapeutics American Depositary Shares presently has a consensus target price of $35.50, suggesting a potential upside of 4.47%. As a group, “Biotechnology” companies have a potential upside of 126.50%. Given Lakefront Biotherapeutics American Depositary Shares’ competitors stronger consensus rating and higher probable upside, analysts plainly believe Lakefront Biotherapeutics American Depositary Shares has less favorable growth aspects than its competitors.

Volatility & Risk

Lakefront Biotherapeutics American Depositary Shares has a beta of 0.22, meaning that its share price is 78% less volatile than the S&P 500. Comparatively, Lakefront Biotherapeutics American Depositary Shares’ competitors have a beta of -1.82, meaning that their average share price is 282% less volatile than the S&P 500.

Earnings and Valuation

This table compares Lakefront Biotherapeutics American Depositary Shares and its competitors gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Lakefront Biotherapeutics American Depositary Shares $1.26 billion $363.05 million -24.10
Lakefront Biotherapeutics American Depositary Shares Competitors $702.34 million $9.48 million -18.76

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than its competitors. Lakefront Biotherapeutics American Depositary Shares is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Lakefront Biotherapeutics American Depositary Shares and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Lakefront Biotherapeutics American Depositary Shares N/A N/A N/A
Lakefront Biotherapeutics American Depositary Shares Competitors -12,323.33% -195.91% -30.60%

Summary

Lakefront Biotherapeutics American Depositary Shares competitors beat Lakefront Biotherapeutics American Depositary Shares on 7 of the 13 factors compared.

About Lakefront Biotherapeutics American Depositary Shares

(Get Free Report)

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company’s pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis.

Receive News & Ratings for Lakefront Biotherapeutics American Depositary Shares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lakefront Biotherapeutics American Depositary Shares and related companies with MarketBeat.com's FREE daily email newsletter.